## Peter A Jones

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1585459/peter-a-jones-publications-by-year.pdf

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

74	28,369	47	77
papers	citations	h-index	g-index
77	31,674 ext. citations	16.1	7.81
ext. papers		avg, IF	L-index

#	Paper	IF	Citations
74	The Human Epigenome <b>2022</b> , 3-25		
73	Oocyte age and preconceptual alcohol use are highly correlated with epigenetic imprinting of a noncoding RNA (). <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2021</b> , 118,	11.5	3
72	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> , <b>2021</b> , 2, 1002-1017	15.4	3
71	Activation of a Subset of Evolutionarily Young Transposable Elements and Innate Immunity Are Linked to Clinical Responses to 5-Azacytidine. <i>Cancer Research</i> , <b>2020</b> , 80, 2441-2450	10.1	15
70	DNA methylation enables transposable element-driven genome expansion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 19359-19366	11.5	35
69	Structure of nucleosome-bound DNA methyltransferases DNMT3A and DNMT3B. <i>Nature</i> , <b>2020</b> , 586, 151-155	50.4	26
68	Epigenetic therapy in immune-oncology. <i>Nature Reviews Cancer</i> , <b>2019</b> , 19, 151-161	31.3	216
67	A phase 1 study of azacitidine combined with chemotherapy in childhood leukemia: a report from the TACL consortium. <i>Blood</i> , <b>2018</b> , 131, 1145-1148	2.2	22
66	A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 6160-6167	12.9	31
65	Nucleosome Occupancy and Methylome Sequencing (NOMe-seq). <i>Methods in Molecular Biology</i> , <b>2018</b> , 1708, 267-284	1.4	13
64	Mother-child transmission of epigenetic information by tunable polymorphic imprinting.  Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E11970-E119	9 <del>77</del> .5	19
63	Dual Inhibition of DNA and Histone Methyltransferases Increases Viral Mimicry in Ovarian Cancer Cells. <i>Cancer Research</i> , <b>2018</b> , 78, 5754-5766	10.1	49
62	Switching roles for DNA and histone methylation depend on evolutionary ages of human endogenous retroviruses. <i>Genome Research</i> , <b>2018</b> , 28, 1147-1157	9.7	47
61	Identifying aggressive prostate cancer foci using a DNA methylation classifier. <i>Genome Biology</i> , <b>2017</b> , 18, 3	18.3	31
60	Down-regulation of ARID1A is sufficient to initiate neoplastic transformation along with epigenetic reprogramming in non-tumorigenic endometriotic cells. <i>Cancer Letters</i> , <b>2017</b> , 401, 11-19	9.9	27
59	Nucleosome Positioning and NDR Structure at RNA Polymerase III Promoters. <i>Scientific Reports</i> , <b>2017</b> , 7, 41947	4.9	21
58	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 2691-27	0 <del>12</del> .9	84

## (2011-2017)

Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 57 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget, **2017**, 8, 35326-35338 52Vitamin C increases viral mimicry induced by 5-aza-24deoxycytidine. Proceedings of the National 56 11.5 110 Academy of Sciences of the United States of America, 2016, 113, 10238-44 Targeting the cancer epigenome for therapy. Nature Reviews Genetics, 2016, 17, 630-41 649 55 30.1 Identification of DNA Methylation-Independent Epigenetic Events Underlying Clear Cell Renal Cell 10.1 54 Carcinoma. Cancer Research, 2016, 76, 1954-64 DNMT3B isoforms without catalytic activity stimulate gene body methylation as accessory proteins 53 17.4 79 in somatic cells. Nature Communications, 2016, 7, 11453 Bivalent Regions of Cytosine Methylation and H3K27 Acetylation Suggest an Active Role for DNA 52 17.6 77 Methylation at Enhancers. Molecular Cell, 2016, 62, 422-431 The role of DNA methylation in directing the functional organization of the cancer epigenome. 62 51 9.7 Genome Research, **2015**, 25, 467-77 DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by 50 56.2 705 Endogenous Transcripts. *Cell*, **2015**, 162, 961-73 Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell, 662 24.3 49 2014, 26, 577-90 Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common 48 3.3 299 human epithelial cancers. Oncotarget, 2014, 5, 587-98 The cancer epigenome. Genome, 2013, 56, 540-1 47 2.4 3 Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine. Oncotarget, 2013, 46 285 3.3 4, 2067-79 Genome-wide mapping of nucleosome positioning and DNA methylation within individual DNA 281 9.7 45 molecules. Genome Research, 2012, 22, 2497-506 Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nature Reviews 44 30.1 3737 Genetics, 2012, 13, 484-92 Allelic methylation levels of the noncoding VTRNA2-1 located on chromosome 5q31.1 predict 2.2 78 43 outcome in AML. Blood, 2012, 119, 206-16 DNA methylation screening identifies driver epigenetic events of cancer cell survival. Cancer Cell, 198 42 24.3 **2012**, 21, 655-667 Cancer genetics and epigenetics: two sides of the same coin?. Cancer Cell, 2012, 22, 9-20 41 784 24.3 Nucleosomes containing methylated DNA stabilize DNA methyltransferases 3A/3B and ensure 6 88 40 faithful epigenetic inheritance. PLoS Genetics, 2011, 7, e1001286

39	Selective anchoring of DNA methyltransferases 3A and 3B to nucleosomes containing methylated DNA. <i>Molecular and Cellular Biology</i> , <b>2009</b> , 29, 5366-76	4.8	167
38	Analysis of individual remodeled nucleosomes reveals decreased histone-DNA contacts created by hSWI/SNF. <i>Nucleic Acids Research</i> , <b>2009</b> , 37, 5279-94	20.1	33
37	Rethinking how DNA methylation patterns are maintained. <i>Nature Reviews Genetics</i> , <b>2009</b> , 10, 805-11	30.1	585
36	Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2008</b> , 105, 12979-84	11.5	289
35	Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. <i>Cancer Cell</i> , <b>2007</b> , 12, 432-44	24.3	168
34	Delivery of 5-aza-2⊌deoxycytidine to cells using oligodeoxynucleotides. <i>Cancer Research</i> , <b>2007</b> , 67, 6400	<b>)-£</b> 0.1	183
33	The epigenomics of cancer. <i>Cell</i> , <b>2007</b> , 128, 683-92	56.2	3514
32	Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. <i>Cancer Cell</i> , <b>2006</b> , 9, 435-43	24.3	1137
31	Identification of DNMT1 (DNA methyltransferase 1) hypomorphs in somatic knockouts suggests an essential role for DNMT1 in cell survival. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 14080-5	11.5	159
30	Overview of cancer epigenetics. <i>Seminars in Hematology</i> , <b>2005</b> , 42, S3-8	4	69
30	Overview of cancer epigenetics. <i>Seminars in Hematology</i> , <b>2005</b> , 42, S3-8  Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , <b>2004</b> , 429, 457-63	4 50.4	69 2442
		<u> </u>	
29	Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , <b>2004</b> , 429, 457-63  Origins of bidirectional promoters: computational analyses of intergenic distance in the human	50.4	2442
29	Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , <b>2004</b> , 429, 457-63  Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. <i>Molecular Biology and Evolution</i> , <b>2004</b> , 21, 463-7  Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. <i>Molecular Cancer</i>	50.4	2442
29 28 27	Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , <b>2004</b> , 429, 457-63  Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. <i>Molecular Biology and Evolution</i> , <b>2004</b> , 21, 463-7  Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 62-72	50.4 8.3 6.6	2442 62 108
29 28 27 26	Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , <b>2004</b> , 429, 457-63  Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. <i>Molecular Biology and Evolution</i> , <b>2004</b> , 21, 463-7  Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 62-72  The fundamental role of epigenetic events in cancer. <i>Nature Reviews Genetics</i> , <b>2002</b> , 3, 415-28  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome	50.4 8.3 6.6	2442 62 108 4311
29 28 27 26 25	Epigenetics in human disease and prospects for epigenetic therapy. <i>Nature</i> , <b>2004</b> , 429, 457-63  Origins of bidirectional promoters: computational analyses of intergenic distance in the human genome. <i>Molecular Biology and Evolution</i> , <b>2004</b> , 21, 463-7  Role of the DNA Methyltransferase Variant DNMT3b3 in DNA Methylation. <i>Molecular Cancer Research</i> , <b>2004</b> , 2, 62-72  The fundamental role of epigenetic events in cancer. <i>Nature Reviews Genetics</i> , <b>2002</b> , 3, 415-28  Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2\(\text{\text{deoxycytidine}}\) (decitabine) treatment. <i>Blood</i> , <b>2002</b> , 100, 2957-64  Cooperativity between DNA methyltransferases in the maintenance methylation of repetitive	50.4 8.3 6.6 30.1	2442 62 108 4311 459

## (1978-2000)

21	PAX6 methylation and ectopic expression in human tumor cells. <i>International Journal of Cancer</i> , <b>2000</b> , 87, 179-85	7.5	66
20	Bladder cancer genotype stability during clinical progression. <i>Genes Chromosomes and Cancer</i> , <b>2000</b> , 29, 26-32	5	11
19	PAX6 methylation and ectopic expression in human tumor cells <b>2000</b> , 87, 179		1
18	Cancer epigenetics comes of age. <i>Nature Genetics</i> , <b>1999</b> , 21, 163-7	36.3	1927
17	DNA methylation as a target for drug design. <i>Pharmaceutical Research</i> , <b>1998</b> , 15, 175-87	4.5	60
16	Early acquisition of homozygous deletions of p16/p19 during squamous cell carcinogenesis and genetic mosaicism in bladder cancer. <i>Oncogene</i> , <b>1998</b> , 17, 3021-7	9.2	27
15	Enhancer-dependent, locus-wide regulation of the imprinted mouse insulin-like growth factor II gene. <i>Journal of Biochemistry</i> , <b>1998</b> , 123, 984-91	3.1	4
14	Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). <i>Nucleic Acids Research</i> , <b>1997</b> , 25, 2529-31	20.1	329
13	p53 and treatment of bladder cancer. <i>Nature</i> , <b>1997</b> , 385, 123-5	50.4	237
12	The rate of CpG mutation in Alu repetitive elements within the p53 tumor suppressor gene in the primate germline. <i>Journal of Molecular Biology</i> , <b>1996</b> , 258, 240-50	6.5	56
11	Methylation inhibitors can increase the rate of cytosine deamination by (cytosine-5)-DNA methyltransferase. <i>Nucleic Acids Research</i> , <b>1996</b> , 24, 3267-75	20.1	34
10	Mutagenicity of nitric oxide is not caused by deamination of cytosine or 5-methylcytosine in double-stranded DNA. <i>Carcinogenesis</i> , <b>1994</b> , 15, 2899-903	4.6	41
9	Mesodermal determination genes: evidence from DNA methylation studies. <i>BioEssays</i> , <b>1988</b> , 8, 100-3	4.1	4
8	Allele-specific methylation of the human c-Ha-ras-1 gene. <i>Cell</i> , <b>1987</b> , 50, 711-7	56.2	76
7	Endothelial Cells Degrade Extracellular Matrix Proteins Produced In Vitro. <i>Thrombosis and Haemostasis</i> , <b>1985</b> , 54, 498-502	7	22
6	5-methylcytosine, gene regulation, and cancer. Advances in Cancer Research, 1983, 40, 1-30	5.9	365
5	Cellular differentiation, cytidine analogs and DNA methylation. <i>Cell</i> , <b>1980</b> , 20, 85-93	56.2	1553
4	Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. <i>Developmental Biology</i> , <b>1978</b> , 66, 57-71	3.1	140

3	Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment. <i>Nature</i> , <b>1977</b> , 267, 364-6	50.4	293
2	Characterisation of human cells transformed in vitro by urethane. <i>Nature</i> , <b>1975</b> , 256, 322-4	50.4	24
1	Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia. <i>Nature Cancer</i> ,	15.4	21